Back to top
more

AtriCure (ATRC)

(Real Time Quote from BATS)

$23.32 USD

23.32
220,865

+0.15 (0.65%)

Updated Apr 24, 2024 03:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (152 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management

by Zacks Equity Research

AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.

Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings

by Zacks Equity Research

The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of 4.55% and 0.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Seeking Clues to AtriCure (ATRC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of AtriCure (ATRC) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Wall Street Analysts Predict a 36.34% Upside in AtriCure (ATRC): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 36.3% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

All You Need to Know About AtriCure (ATRC) Rating Upgrade to Buy

by Zacks Equity Research

AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AtriCure (ATRC) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of 55.56% and 3.05%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of 32.35% and 6.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AtriCure (ATRC) Moves 7.5% Higher: Will This Strength Last?

by Zacks Equity Research

AtriCure (ATRC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of 50% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Canopy Growth Corporation (CGC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -169.23% and 11.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of -8% and 2.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Baxter International (BAX) Q3 Earnings Match Estimates

by Zacks Equity Research

Baxter (BAX) delivered earnings and revenue surprises of 0% and 0.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Nephros Inc. (NEPH) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Nephros Inc. (NEPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of -6.67% and 6.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of -22.22% and 4.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Stryker (SYK) delivered earnings and revenue surprises of 2.07% and 1.79%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Think AtriCure (ATRC) Could Surge 52%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of -15.38% and 0.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) Q4 Earnings Top Estimates

by Zacks Equity Research

Bio-Rad (BIO) delivered earnings and revenue surprises of 11.85% and 0.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

AtriCure (ATRC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 63.89% and 3.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?